This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2011 Mar 25;331(6024):1551-2.

doi: 10.1126/science.331.6024.1551.

Brothers in arms against cancer

PMID: 21436441
DOI: 10.1126/science.331.6024.1551

Brothers in arms against cancer

Mitch Leslie. Science. 2011.

. 2011 Mar 25;331(6024):1551-2.

doi: 10.1126/science.331.6024.1551.

Author

PMID: 21436441
DOI: 10.1126/science.331.6024.1551

No abstract available

PubMed Disclaimer

Similar articles

Therapeutic prospects for p73 and p63: rising from the shadow of p53.
Vilgelm A, El-Rifai W, Zaika A. Vilgelm A, et al. Drug Resist Updat. 2008 Aug-Oct;11(4-5):152-63. doi: 10.1016/j.drup.2008.08.001. Epub 2008 Sep 17. Drug Resist Updat. 2008. PMID: 18801697 Free PMC article. Review.
P53 family activities in development and cancer: relationship to melanocyte and keratinocyte carcinogenesis.
Johnson J, Lagowski J, Sundberg A, Kulesz-Martin M. Johnson J, et al. J Invest Dermatol. 2005 Nov;125(5):857-64. doi: 10.1111/j.0022-202X.2004.23920.x. J Invest Dermatol. 2005. PMID: 16297181 Review. No abstract available.
The role of p53 protein family in gastrointestinal malignancies.
Zaika AI, El-Rifai W. Zaika AI, et al. Cell Death Differ. 2006 Jun;13(6):935-40. doi: 10.1038/sj.cdd.4401897. Cell Death Differ. 2006. PMID: 16557273 Review. No abstract available.
The functional domains in p53 family proteins exhibit both common and distinct properties.
Harms KL, Chen X. Harms KL, et al. Cell Death Differ. 2006 Jun;13(6):890-7. doi: 10.1038/sj.cdd.4401904. Cell Death Differ. 2006. PMID: 16543939 Review. No abstract available.
p73: a complex gene for building a complex brain.
Meyer G. Meyer G. Cell Cycle. 2011 Apr 15;10(8):1188-9. doi: 10.4161/cc.10.8.15297. Epub 2011 Apr 15. Cell Cycle. 2011. PMID: 21441779 No abstract available.

See all similar articles

Cited by

SMG1 and CDK12 Link ΔNp63α Phosphorylation to RNA Surveillance in Keratinocytes.
Bamberger C, Pankow S, Yates JR 3rd. Bamberger C, et al. J Proteome Res. 2021 Dec 3;20(12):5347-5358. doi: 10.1021/acs.jproteome.1c00427. Epub 2021 Nov 11. J Proteome Res. 2021. PMID: 34761935 Free PMC article.
TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yau C, Ng S, Lee SK, Romano RA, Davis S, Walker RL, Xiao W, Sun H, Wei L, Sinha S, Benz CC, Stuart JM, Meltzer PS, Van Waes C, Chen Z. Si H, et al. Oncogene. 2016 Nov 3;35(44):5781-5794. doi: 10.1038/onc.2016.112. Epub 2016 May 2. Oncogene. 2016. PMID: 27132513 Free PMC article.
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.
Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS. Hong B, et al. Cancer Res. 2014 Feb 15;74(4):1153-65. doi: 10.1158/0008-5472.CAN-13-0955. Epub 2013 Nov 18. Cancer Res. 2014. PMID: 24247721 Free PMC article.
CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion.
Sasaki Y, Koyama R, Maruyama R, Hirano T, Tamura M, Sugisaka J, Suzuki H, Idogawa M, Shinomura Y, Tokino T. Sasaki Y, et al. Cancer Biol Ther. 2012 Dec;13(14):1512-21. doi: 10.4161/cbt.22280. Epub 2012 Sep 18. Cancer Biol Ther. 2012. PMID: 22990203 Free PMC article.
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.
Melino G. Melino G. Cell Death Differ. 2011 Sep;18(9):1487-99. doi: 10.1038/cdd.2011.81. Epub 2011 Jul 15. Cell Death Differ. 2011. PMID: 21760596 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.